Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tekmira Pharmaceuticals, a biopharmaceutical company focused on advancing novel RNAi therapeutics, has received two patents from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
The two patents cover lipid nanoparticle (LNP) manufacturing process and the chemical modification of siRNA to mitigate immune stimulation.
Tekmira Pharma said with the issuance of US patent no 7,915,399, the USPTO has granted claims covering the modification of siRNA sequences to prevent immune stimulation.
With the issuance of US patent no. 7,915,399, the USPTO has granted claims broadly covering the modification of siRNA sequences to prevent immune stimulation.
Tekmira Pharma president and CEO Mark Murray said they continue to innovate and to protect all aspects of their proprietary LNP technology, which is the gold standard in siRNA delivery.